Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

New Frontiers in the Treatment of MSI High Endometrial Cancer

Release Date: December 31, 2017
Expiration Date: December 31, 2018
Media: Internet - based


Activity Overview

Oncology Briefings™ is an online interactive monograph and print supplement that includes an overview of New Frontiers in the Treatment of MSI-High Endometrial Cancer. New clinical treatment options for patients with microsatellite instability‒high (MSI-H) endometrial cancer (EC) continue to be investigated at a rapid pace, including the use of checkpoint inhibitors that are being investigated across a variety of advanced cancers that demonstrate MSI-H, including EC. This education activity aims to update oncology healthcare professionals who participate in the multidisciplinary treatment of patients in gynecologic malignancies by providing expert guidance, interpretation, and opinions on the importance and potential impact of immunotherapeutic approaches in the management of MSI-high EC. This activity is designed to aid physicians in assessing the biologic rationale for mismatch repair deficiency (dMMR) or MSI-H deficiency as an immunogenic tumor, and its role in the identification of appropriate candidates for immunotherapeutic strategies. Given the inherent unfamiliarity with immunotherapeutic approaches among many who treat gynecologic cancers, and this emerging novel way to personalize care in patients with these malignancies, this educational initiative is a targeted update for clinicians on the rationale for these approaches, the latest clinical trial results from completed and ongoing trials, personalized methods being explored to identify patient populations most likely to benefit from these strategies, and proactive measures to mitigate and manage the impact of treatment-related toxicities. A national thought leader interprets presented data, and provides key take-home points and clinical pearls for practice to place the content into clear perspective. Audio sidebars, figures, and tables provide supporting evidence for this activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

CME Activity Table of Contents

  • Introduction
  • Immunotherapeutic Approaches to dMMR/MSI-H in EC
  • Best Practices for Patients and Families
  • Proactively Mitigating Treatment-Related Toxicities

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, "Educational Content/Audio Files" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational initiative is directed toward medical oncologists, gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists who treat patients with gynecologic malignancies. Obstetrician/gynecologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of gynecologic malignancies are also invited to participate.

Learning Objectives

Upon completion of this activity, you should be better able to:

  • Explain guideline recommendations for dMMR/MSI-H testing in patients with endometrial cancer (EC), the biologic rationale for dMMR-MSI-H as an immunogenic tumor, and its role in the identification of appropriate candidates for immunotherapeutic strategies and/or referral to clinical trials
  • Evaluate current and emerging clinical trial evidence concerning the use of immunotherapeutic approaches in patients with dMMR/MSI-H EC
  • Discuss best practices to effectively counsel patients and their families concerning dMMR-MSI-H EC, and how that impacts prognosis, decision making for family members, and therapeutic options

Faculty, Staff, and Planners' Disclosures


Bradley J. Monk, MD, FACOG, FACS
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Phoenix Creighton University School of Medicine at St. Joseph's Hospital
Phoenix, AZ

Disclosure: Consultant: AbbVie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis, Genmab, Gradalis, Immunogen, Incyte, Insys, Mateon, Merck, Myriad, Perthera, Pfizer, Precision Oncology, Roche/Genentech, Tesaro, Inc, VBL. Consultant: AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro, Inc.

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By